These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 16223396)

  • 1. The post-operative analgesic efficacy and tolerability of lumiracoxib compared with placebo and naproxen after total knee or hip arthroplasty.
    Chan VW; Clark AJ; Davis JC; Wolf RS; Kellstein D; Jayawardene S
    Acta Anaesthesiol Scand; 2005 Nov; 49(10):1491-500. PubMed ID: 16223396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of lumiracoxib 200 mg once daily for treatment of primary dysmenorrhea: results from two randomized controlled trials.
    Daniels S; Gitton X; Zhou W; Stricker K; Barton S
    J Womens Health (Larchmt); 2008 Apr; 17(3):423-37. PubMed ID: 18373490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215].
    Wittenberg RH; Schell E; Krehan G; Maeumbaed R; Runge H; Schlüter P; Fashola TO; Thurston HJ; Burger KJ; Trechsel U
    Arthritis Res Ther; 2006; 8(2):R35. PubMed ID: 16469112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo.
    Sheldon E; Beaulieu A; Paster Z; Dutta D; Yu S; Sloan VS
    Clin Ther; 2005 Jan; 27(1):64-77. PubMed ID: 15763607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of lumiracoxib in the treatment of primary dysmenorrhoea.
    Bitner M; Kattenhorn J; Hatfield C; Gao J; Kellstein D
    Int J Clin Pract; 2004 Apr; 58(4):340-5. PubMed ID: 15161117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised, double-blind study comparing lumiracoxib with naproxen for acute musculoskeletal pain.
    Kyle C; Zachariah J; Kinch H; Ellis G; Andrews C; Adekunle F
    Int J Clin Pract; 2008 Nov; 62(11):1684-92. PubMed ID: 19143855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analgesic efficacy of a single dose of lumiracoxib compared with rofecoxib, celecoxib and placebo in the treatment of post-operative dental pain.
    Kellstein D; Ott D; Jayawardene S; Fricke J
    Int J Clin Pract; 2004 Mar; 58(3):244-50. PubMed ID: 15117090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.
    Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Matchaba P; Gimona A; Hawkey CJ;
    Lancet; 2004 Aug 21-27; 364(9435):665-74. PubMed ID: 15325831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies.
    Daniels S; Robbins J; West CR; Nemeth MA
    Clin Ther; 2009 Jun; 31(6):1192-208. PubMed ID: 19695387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib.
    Tannenbaum H; Berenbaum F; Reginster JY; Zacher J; Robinson J; Poor G; Bliddal H; Uebelhart D; Adami S; Navarro F; Lee A; Moore A; Gimona A
    Ann Rheum Dis; 2004 Nov; 63(11):1419-26. PubMed ID: 15020310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib.
    Fleischmann R; Sheldon E; Maldonado-Cocco J; Dutta D; Yu S; Sloan VS
    Clin Rheumatol; 2006 Feb; 25(1):42-53. PubMed ID: 16132165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
    Matchaba P; Gitton X; Krammer G; Ehrsam E; Sloan VS; Olson M; Mellein B; Hoexter G; Orloff J; Garaud JJ
    Clin Ther; 2005 Aug; 27(8):1196-214. PubMed ID: 16199245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.
    Farkouh ME; Kirshner H; Harrington RA; Ruland S; Verheugt FW; Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Gimona A; Matchaba P; Hawkey CJ; Chesebro JH;
    Lancet; 2004 Aug 21-27; 364(9435):675-84. PubMed ID: 15325832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lumiracoxib 400 mg compared with celecoxib 400 mg and placebo for treating pain following dental surgery: a randomized, controlled trial.
    Fricke J; Davis N; Yu V; Krammer G
    J Pain; 2008 Jan; 9(1):20-7. PubMed ID: 17933588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib.
    Farkouh ME; Greenberg JD; Jeger RV; Ramanathan K; Verheugt FW; Chesebro JH; Kirshner H; Hochman JS; Lay CL; Ruland S; Mellein B; Matchaba PT; Fuster V; Abramson SB
    Ann Rheum Dis; 2007 Jun; 66(6):764-70. PubMed ID: 17412741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis.
    Geusens P; Alten R; Rovensky J; Sloan VS; Krammer G; Kralidis G; Richardson P
    Int J Clin Pract; 2004 Nov; 58(11):1033-41. PubMed ID: 15605667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial.
    Schnitzer TJ; Beier J; Geusens P; Hasler P; Patel SK; Senftleber I; Gitton X; Moore A; Sloan VS; Poór G
    Arthritis Rheum; 2004 Aug; 51(4):549-57. PubMed ID: 15334426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does perioperative administration of rofecoxib improve analgesia after spine, breast and orthopaedic surgery?
    Riest G; Peters J; Weiss M; Pospiech J; Hoffmann O; Neuhäuser M; Beiderlinden M; Eikermann M
    Eur J Anaesthesiol; 2006 Mar; 23(3):219-26. PubMed ID: 16430794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib.
    Lehmann R; Brzosko M; Kopsa P; Nischik R; Kreisse A; Thurston H; Litschig S; Sloan VS
    Curr Med Res Opin; 2005 Apr; 21(4):517-26. PubMed ID: 15899100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lumiracoxib in the treatment of osteoarthritis, rheumatoid arthritis and acute postoperative dental pain: results of three dose-response studies.
    Schnitzer TJ; Gitton X; Jayawardene S; Sloan VS
    Curr Med Res Opin; 2005 Jan; 21(1):151-61. PubMed ID: 15881487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.